Navigation Links
Mylan Confirms Four First-to-File Challenges
Date:3/26/2009

PITTSBURGH, March 26 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it and/or a subsidiary have been sued in connection with four separate "first-to-file" Abbreviated New Drug Applications (ANDA) filed with the U.S. Food and Drug Administration (FDA).

Mylan and Alphapharm Pty. Ltd were sued by Sepracor Inc. in the U.S. District Court of New Jersey in connection with the ANDA filing for Eszopiclone Tablets, 1 mg, 2 mg and 3 mg. Eszopiclone Tablets are the generic version of Sepracor's insomnia treatment Lunesta(R) Tablets, which had approximately $796 million in U.S. sales for the twelve months ending Dec. 31, 2008, according to IMS Health.

Mylan Pharmaceuticals Inc. was sued by OSI Pharmaceuticals Inc., Pfizer Inc. and Genentech Inc. in the U.S. District Court in Delaware in connection with the ANDA filing for Erlotinib Hydrochloride (HCl) Tablets, 25 mg, 100 mg and 150 mg. Erlotinib HCl Tablets are the generic version of OSI Pharmaceuticals' lung cancer treatment Tarceva(R) Tablets, which had approximately $492 million in U.S. sales for the twelve months ending Dec. 31, 2008, according to IMS Health.

Mylan, Mylan Pharmaceuticals and Matrix Laboratories Limited, in which Mylan owns a majority interest, were sued by Shire Canada Inc., Shire International Licensing B.V. and Shire U.S. Inc. in the U.S. District Court for the Southern District of New York in connection with the ANDA filing for Lanthanum Carbonate Chewable Tablets, 500 mg, 750 mg and 1000 mg. Lanthanum Carbonate Chewable Tablets are the generic version of Shire's kidney disease treatment Fosrenol(R), which had approximately $108 million in U.S. sales for the twelve months ending Dec. 31, 2008, according to IMS Health.

Mylan Pharmaceuticals was sued by Galderma Laboratories Inc., Galderma Laboratories LP, The R
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
2. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
3. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
4. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
7. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
10. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
11. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... PuraMed BioScience ® , Inc., (OTCBB: ... (OTC) medicinal and healthcare products, announced that Ludlow ... based on low market capitalization valuation. ... Product to Treat Migraine Headaches , Clinical ... , Currently Available Nationwide at Walgreen,s and ...
(Date:5/23/2013)... Calif. , May 23, 2013  Saddleback Memorial ... recently became the first hospital on the West ... technology. This new surgical option provides women with a ... Marc Winter , M.D., a ... and surgeon and medical director of minimally invasive surgery ...
(Date:5/23/2013)... 23, 2013 Northwest Biotherapeutics (NASDAQ: ... ® personalized immune therapies for solid tumor cancers, ... this year,s American Society Of Clinical Oncology (ASCO) meeting ... leadership role in immune therapy.  (Logo: ... is the pre-eminent conference focused on clinical treatment of ...
(Date:5/23/2013)... May 23, 2013 Pusan National University ... private biotherapeutics and contract research company focused on ... cancer, announced today a publication reporting the induction ... the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; ... published in the May 15 th , 2013 ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... , ROCKAWAY, N.J., Dec. 14 ... Approach , published by the Infusion Nurses ... extravasation.(1) Anthracyclines are a group of chemotherapy medications including ... the treatment of various types of cancer since the early ...
... , WALTHAM, Mass., Dec. ... that it has signed a new, three-year master services ... and services that serve patients in approximately 100 countries. ... for translation of the company,s online content, which includes ...
... WALTHAM, Mass., Dec. 14 Decision Resources, one of the world,s ... that, owing to the launches of several new agents, the atrial ... in 2008 to $6.1 billion in 2018 in the United States, ... new Pharmacor report entitled Atrial Fibrillation finds that a ...
Cached Biology Technology:Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 2Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 3The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2
(Date:5/22/2013)... fuel cell powered buses, including a team from ... degradation processes and bus membrane durability. , The ... stressors in the operating cycle of the bus ... the study, led by SFU graduate student Natalia ... at Burnaby-based Ballard Power Systems and funded by ...
(Date:5/22/2013)... drastically reduces the time and effort needed to ... biotechnology, scientists are reporting. Published in the journal ... the way for more rapid development of designer ... activities. , Keith Shearwin and colleagues explain that ... material DNA into a bacterium,s genome is critical ...
(Date:5/22/2013)... how climate change will affect interactions between species in ... of Animal Ecology . This knowledge, they say, is ... how species are likely to be impacted by rising ... among biologists that climate change is affecting how species ... to have very important consequences for the stability and ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5
... new genetic disease that can lead to severe liver damage. ... liver cells are exposed to the toxic components of the ... cells into connective tissue with a gradual loss of liver ... cirrhosis of unknown origin and open up a new approach ...
... one of the "fathers" of the field of ... seventh annual American Association for Cancer Research (AACR)-Prevent ... Research. The award is given annually to ... of cancer prevention research in basic, translational, clinical, ...
... a simple gene-based blood test that more accurately and ... current tests. The test, a measure of inflammatory gene ... backlog of promising medications now hung up in clinical ... small "proof-of-principal" trial in the online version of ...
Cached Biology News:Toxic bile damages the liver 2Meyskens honored with AACR-Prevent Cancer Foundation award 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 3
Request Info...
Polyclonal Antibody to CLAN...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: